Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hypera S.A. (HYPE3.SA)
BRL20.95
-0.08 (-0.38%)
BR SAO Healthcare Drug Manufacturers - Specialty & Generic
Address
Av. Magalhães de Castro, 4800 05676-120
São Paulo, SP, BR
São Paulo, SP, BR
CEO
Breno Toledo Pires de Oliveira
Website
hyperapharma.com.br
IPO
2008-04-18
ISIN BRHYPEACNOR0
Also trades on
B3 S.A. · HYPE3.SA (BRL)
Other OTC · HYPMY (USD)
Description
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
BRL20.95
-0.08 (-0.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.09
Float Shares
433.34M
Free Float %
61.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.23% | -3.90% | -2.75% | -5.07% | -18.25% | -6.09% | -13.74% | -46.79% | -40.48% | -24.19% | +156.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
20.95
DCF (Unlevered)
30.77
+46.9%
DCF (Levered)
14.51
-30.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
64% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 5 | +1 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.36
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.5% Q1'26: +86.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11.9% Q1'26: +345.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+17.3% Q1'26: +6.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.6% ★ Q1'26: +25.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.5% ★ Q1'26: +9.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.62× Q1'26: 3.71× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 7 EPS Ana. |
Dec 2027 12 Rev. Ana. 7 EPS Ana. |
Dec 2028 10 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.96B
est: 5.19B (-43.0%)
|
3.23B
est: 3.29B (-1.9%)
|
3.50B
est: 3.66B (-4.3%)
|
3.72B
est: 3.82B (-2.4%)
|
3.29B
est: 3.37B (-2.4%)
|
4.09B
est: 4.08B (+0.3%)
|
5.94B
est: 5.93B (+0.1%)
|
7.55B
est: 7.43B (+1.6%)
|
7.91B
est: 8.00B (-1.1%)
|
7.44B
est: 7.44B (+0.0%)
|
7.70B
est: 7.70B (+0.0%)
|
9.13B
9.01B – 9.27B
+18.6% YoY
|
9.95B
8.74B – 10.52B
+9.0% YoY
|
10.86B
10.83B – 10.88B
+9.1% YoY
|
11.99B
11.16B – 12.44B
+10.5% YoY
|
| EBITDA |
992.48M
est: 1.84B (-46.1%)
|
1.14B
est: 1.17B (-2.8%)
|
1.35B
est: 1.30B (+4.0%)
|
1.36B
est: 1.35B (+0.2%)
|
1.26B
est: 1.20B (+5.6%)
|
1.55B
est: 1.45B (+6.8%)
|
2.18B
est: 2.11B (+3.4%)
|
2.77B
est: 2.64B (+5.0%)
|
2.88B
est: 2.66B (+8.1%)
|
2.23B
est: 2.47B (-9.8%)
|
2.05B
est: 2.56B (-19.8%)
|
3.04B
3.00B – 3.08B
+18.6% YoY
|
3.31B
2.91B – 3.50B
+9.0% YoY
|
3.61B
3.60B – 3.62B
+9.1% YoY
|
3.99B
3.71B – 4.14B
+10.5% YoY
|
| EBIT |
885.50M
est: 1.69B (-47.7%)
|
1.07B
est: 1.07B (-0.3%)
|
1.28B
est: 1.19B (+7.3%)
|
1.27B
est: 1.25B (+2.1%)
|
1.14B
est: 1.10B (+3.8%)
|
1.42B
est: 1.33B (+6.7%)
|
2.04B
est: 1.94B (+5.6%)
|
2.60B
est: 2.42B (+7.2%)
|
2.64B
est: 2.41B (+9.3%)
|
1.95B
est: 2.25B (-13.1%)
|
1.74B
est: 2.32B (-25.3%)
|
2.76B
2.72B – 2.80B
+18.6% YoY
|
3.00B
2.64B – 3.18B
+9.0% YoY
|
3.28B
3.27B – 3.28B
+9.1% YoY
|
3.62B
3.37B – 3.75B
+10.5% YoY
|
| Net Income |
559.87M
est: 391.44M (+43.0%)
|
1.18B
est: 731.52M (+61.0%)
|
964.94M
est: 931.14M (+3.6%)
|
1.13B
est: 1.13B (+0.1%)
|
1.16B
est: 1.21B (-3.6%)
|
1.30B
est: 1.25B (+4.0%)
|
1.33B
est: 1.47B (-9.2%)
|
1.70B
est: 1.71B (-0.9%)
|
1.65B
est: 1.69B (-2.7%)
|
1.34B
est: 1.34B (-0.2%)
|
1.20B
est: 1.20B (-0.1%)
|
1.64B
1.53B – 1.75B
+37.3% YoY
|
2.04B
1.91B – 2.18B
+24.4% YoY
|
2.33B
2.17B – 2.49B
+14.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
1.25B
est: 1.39B (-9.8%)
|
1.26B
est: 882.20M (+42.8%)
|
1.44B
est: 979.65M (+46.5%)
|
1.18B
est: 1.02B (+15.5%)
|
1.02B
est: 904.31M (+12.9%)
|
1.21B
est: 1.09B (+10.7%)
|
1.55B
est: 1.59B (-2.6%)
|
1.85B
est: 1.99B (-6.9%)
|
2.00B
est: 2.14B (-6.9%)
|
2.13B
est: 1.99B (+6.7%)
|
2.27B
est: 2.06B (+10.2%)
|
2.44B
2.41B – 2.48B
+18.6% YoY
|
2.66B
2.34B – 2.82B
+9.0% YoY
|
2.91B
2.90B – 2.91B
+9.1% YoY
|
3.21B
2.99B – 3.33B
+10.5% YoY
|
| EPS |
0.89
est: 0.61 (+45.0%)
|
1.87
est: 1.15 (+63.1%)
|
1.53
est: 1.46 (+4.8%)
|
1.79
est: 1.77 (+1.2%)
|
1.84
est: 1.89 (-2.8%)
|
2.05
est: 1.95 (+5.0%)
|
2.10
est: 2.30 (-8.6%)
|
2.68
est: 2.68 (-0.1%)
|
2.61
est: 2.68 (-2.5%)
|
2.12
est: 2.13 (-0.6%)
|
1.87
est: 1.82 (+2.9%)
|
2.61
2.38 – 2.73
+43.4% YoY
|
3.14
2.97 – 3.39
+20.7% YoY
|
3.64
3.37 – 3.87
+15.6% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.94B
OE per share TTM
3.04
Owner's Yield
13.97%
Maintenance CapEx ratio
95.74%
Maint CapEx / Avg PPE
43.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 72 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Brazil Small-Cap ETF EWZS | 2.18% | 5.28M | 0.59% |
| 2 | Invesco FTSE Emerging Markets High Dividend Low Volatility UCITS ETF EMHD.L | 0.50% | 1.43M | 0.49% |
| 3 | Franklin FTSE Brazil ETF FLBR | 0.33% | 1.80M | 0.19% |
| 4 | Franklin FTSE Brazil UCITS ETF FLXB.L | 0.33% | 520.6K | 0.19% |
| 5 | Franklin FTSE Latin America ETF FLLA | 0.19% | 203.1K | 0.19% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.12% | 145.8K | 0.42% |
| 7 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.08% | 294.7K | 0.72% |
| 8 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.08% | 295.0K | 0.44% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.08% | 458.6K | 0.55% |
| 10 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.07% | 258.1K | 0.74% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
165.6K
Shares Outstanding
703.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Breno Toledo Pires de Oliveira | Chief Executive Officer | — | male |
| Hélio Segouras | Head of Consumer Health | — | male |
| Luiz Eduardo Sales Clavis | Vice President of Commercial & Marketing | — | male |
| Mauricio Christovam | Senior Human Resources Officer | — | — |
| Rafael Vito Batista | Chief Operations Officer | — | male |
| Ramon Sanches Frutuoso Silva | Chief Financial Officer & Investor Relation Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HYPE3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
